Novartis bags three new approvals for Ilaris
Novartis has picked up three new indications for its anti-inflammatory Ilaris in the US, allowing its use to treat three rare and distinct types of Periodic Fever Syndromes.
Read More
Tag: Periodic Fever Syndromes
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
